Page 4,524«..1020..4,5234,5244,5254,526..4,5304,540..»

First stem cell research paves way for new treatments for bipolar disorder

Posted: Published on March 27th, 2014

Home > News > health-news Washington, Mar 26 : New stem cell research published by scientists from the University of Michigan Medical School, and fueled by the Heinz C. Prechter Bipolar Research Fund, open doors to potential new treatments for bipolar disorder. The team used skin from people with bipolar disorder to derive the first-ever stem cell lines specific to the condition. They reported how they transformed the stem cells into neurons, similar to those found in the brain - and compared them to cells derived from people without bipolar disorder. The comparison revealed very specific differences in how these neurons behave and communicate with each other, and identified striking differences in how the neurons respond to lithium, the most common treatment for bipolar disorder. It's the first time scientists have directly measured differences in brain cell formation and function between people with bipolar disorder and those without. The research team, are from the Medical School's Department of Cell and Developmental Biology and Department of Psychiatry, and U-M's Depression Center, used a type of stem cell called induced pluripotent stem cells, or iPSCs. By taking small samples of skin cells and exposing them to carefully controlled conditions, the team coaxed … Continue reading →

Posted in Stem Cell Research | Comments Off on First stem cell research paves way for new treatments for bipolar disorder

Electroacupuncture at Conception and Governor vessels and hUCB-MSCs for cerebral ischemia

Posted: Published on March 27th, 2014

PUBLIC RELEASE DATE: 26-Mar-2014 Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research Mesenchymal stem cell transplantation is a novel means of treating cerebral ischemia/reperfusion, and can promote angiogenesis and neurological functional recovery. Acupuncture at Conception and Governor vessels also has positive effects as a treatment for cerebral ischemia/reperfusion. Therefore, Prof. Haibo Yu and co-workers from Affiliated Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine in China hypothesized that electro-acupuncture at Conception and Governor vessels plus mesenchymal stem cell transplantation may have better therapeutic effects on the promotion of angiogenesis and recovery of neurological function than either treatment alone. In their study reported in the Neural Regeneration Research (Vol. 9, No. 1, 2014), human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) were isolated, cultured and transplanted into the brains of cerebral ischemia/reperfusion rats. Electro-acupuncture was also applied. The researchers found that the combined intervention provided a better outcome than mesenchymal stem cell transplantation alone, demonstrating that electro-acupuncture at Conception and Governor vessels and mesenchymal stem cell transplantation have synergetic effects on promoting neurological function recovery and angiogenesis in rats after cerebral ischemia/reperfusion. ### Article: "Electro-acupuncture at Conception and Governor vessels and transplantation of umbilical cord bloodderived mesenchymal stem cells … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Electroacupuncture at Conception and Governor vessels and hUCB-MSCs for cerebral ischemia

Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy

Posted: Published on March 26th, 2014

Retinitis pigmentosa is the most common inherited eye disease. Mutations in the gene for rhodopsin, the pigment for photoreceptor cells in the retina responsible for the perception of light, account for 15 percent of retinitis pigmentosa cases. CHOP spinout Spark Therapeutics, which has a late stage retinitis pigmentosa gene therapy treatment under development, is collaborating with Ireland-based biopharma company Genable Technologies, according to a company statement. The deal will focus on Genables lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa, called GT038. Under the deal terms, Genable will license certain manufacturing patents from Spark. Philadelphia-based Spark will be the exclusive manufacturer of the product and provide development advice and expertise to Genable to help in its development of GT038. In exchange, Spark received an initial payment and will receive subsequent milestone payments and royalties on future sales of GT038, and near-term revenue from the manufacture and supply of the product, according to the statement. In response to emailed questions a spokeswoman for Spark Therapeutics said: Generally, the company recognizes that there are a significant number of severe genetic diseases without effective treatments in therapeutic areas where it has significant expertise (for example, inherited blindness, hematologic disorders, neurodegenerative diseases), and … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy

Dublin's Genable partners with US firm

Posted: Published on March 26th, 2014

Wednesday, March 26 12:07:25 Genable Technologies, the venture-capital-backed Dublin-based pharma company specialising in fighting blindness, has entered in to a collaborative deal with Spark in the US to find a therapy against inherited blindness. They both announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. Under the terms of the collaboration, Genable will license certain adeno-associated virus (AAV) vector manufacturing patents from Spark. The parties have entered into a broad agreement in which Spark will be the exclusive manufacturer of the product and provide development advice and expertise to Genable to help in the ongoing development of GT038. Spark will receive milestone payments and royalties on future sales of GT038, as well as near-term revenue from the manufacture and supply of product. "We are excited to apply our deep expertise in AAV clinical development and manufacturing to augment Genable's great work, and expand the number of debilitating diseases of the eye that can be addressed through gene therapy," said Jeffrey D. Marrazzo, Spark Therapeutics co-founder, president and CEO. Dr. Jason Loveridge, CEO of Genable Technologies commented, "We have chosen Spark as our partner to advise, … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Dublin's Genable partners with US firm

Dublin tech company to work with US biopharma group

Posted: Published on March 26th, 2014

Genable Technologies founder and director Prof Jane Farrar. Photo: Aidan Crawley Genable Technologies, a Dublin company targeting genetic diseases causing blindness, has announced a collaboration with US biopharma group Spark Therapeutics. The academics behind Genable Technologies have spent over 20 years looking at one form of inherited blindness rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO-adRP) in which a genetic mutation leads to damage of the retina and a gradual loss of sight. There is no approved drug treatment on the market for the condition, which affects an estimated 30,000 patients worldwide. In 2011, Genable raised $5 million in an exercise led by Fountain Healthcare Partners and involving existing investor Delta Partners, to develop its lead drug candidate GT038. While Genable will licence certain intellectual property from Spark under the terms of the collaboration, it will retain the full IP on GT038, the company said yesterday. The drug is expected to enter full clinical trials next year. Spark will become the exclusive manufacturer of the drug and will receive milestone payments and royalties on future sales. The collaboration with Spark provides an exciting opportunity to greatly expedite development of Genables novel therapy targeted towards RHO-adRP, said Prof Jane Farrar, founder and director, … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Dublin tech company to work with US biopharma group

Medical equipment seized from Kennesaw med spa

Posted: Published on March 26th, 2014

Dad believes med spa victim's spirit appears during interview Dad believes med spa victim's spirit appears during interview Updated: Thursday, March 20 2014 5:23 PM EDT2014-03-20 21:23:50 GMT Updated: Monday, March 3 2014 6:37 PM EST2014-03-03 23:37:19 GMT Updated: Wednesday, February 19 2014 11:05 AM EST2014-02-19 16:05:01 GMT Updated: Wednesday, February 19 2014 11:04 AM EST2014-02-19 16:04:29 GMT A metro Atlanta doctor who recently had her license suspended by the Georgia Medical Board ran into more problems Tuesday. This time, Dr. Nedra Dodds and Opulence Aesthetic Medicine encountered financial trouble. CBS46 obtained a court order from Cobb County Superior Court which states that the Kennesaw med spa defaulted on a $1.2 million business loan. As a result, the bank seized all medical equipment from the business as collateral. "All we were told was is that there was a lien put against some of the equipment by a bank," said Rich Johnson with SE Medical Systems. Johnson was called out to the business on a whim Tuesday to properly dismantle anesthesia equipment so it could be safely removed. "Some of the equipment is very delicate and can't be moved as is so we were called in to remove the monitoring systems, … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Medical equipment seized from Kennesaw med spa

Stemedica Announces International Educational Collaboration With Smart Living

Posted: Published on March 26th, 2014

San Diego, CA (PRWEB) March 26, 2014 Stemedica Cell Technologies, Inc., a specialty biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and Smart Living, a subsidiary of Smart Global, a $2 billion (USD) globally diversified conglomerate, are pleased to announce an international educational collaboration. Smart Living currently organizes dynamic One World educational conferences designed to introduce breakthrough technologies and educational programs focused on health care and regenerative medicine to countries throughout the world. High profile leaders in medicine, science, business, education, government and community organizers are brought together at these international forums to participate in presentations, discussions and educational programs. Stemedica, a global leader in regenerative medicine focused on stem cell research and clinical trials, has been selected to introduce breakthrough technologies in the dynamic field of stem cells and their role in translational medicine. In addition to the educational outreach, Smart Living is making significant advances in health care with its Smart Health City model. This model, anticipated to go global, was developed to be an all-inclusive health care destination offering services including multispecialty hospitals, medical office buildings, medical rehabilitation centers, international patient care centers, medical education and training, clinical research, on campus staff residence, research and technology … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Stemedica Announces International Educational Collaboration With Smart Living

Stem Cell Treatment, Bio Identical Hormones in New York NY 10023 – Video

Posted: Published on March 26th, 2014

Stem Cell Treatment, Bio Identical Hormones in New York NY 10023 We offer a multitude of medical services as part of our preventative medical treatment focused on regaining and maintaining optimal health, vitality and vigo... By: MSPEG8000 … Continue reading →

Comments Off on Stem Cell Treatment, Bio Identical Hormones in New York NY 10023 – Video

Stem cell trials on tackling osteoarthritis may lead to treatment in five years

Posted: Published on March 26th, 2014

The trials involve injecting adult stem cells derived from adipose tissue or fat into cartilage to stimulate its regeneration Researchers in Galway predict that stem cells could be used to treat osteoarthritis within five years, following successful initial clinical trials. The trials involve injecting adult stem cells derived from adipose tissue or fat into cartilage to stimulate its regeneration. Osteoarthritis affects some 70 million people across the EU, and current treatment is limited to surgery or pain management. Some 400,000 people in Ireland are affected by this most common form of human arthritis, which is characterised by the often very painful degeneration of cartilage in joints. Successful trial NUI Galway (NUIG) scientists, who are part of a 9 million EU-funded project, have just finished the successful phase one clinical trial. Prof Frank Barry, scientific director of NUIGs Regenerative Medicine Institute (Remedi), yesterday said the positive early results indicate a treatment was in sight. From the clinical trials conducted so far, we have seen the first signs of finding a cure for this truly incapacitating disease which affects so many, Prof Barry said. Using the patients own stem cells we have been able to treat their diseased joints, and relieve their … Continue reading →

Comments Off on Stem cell trials on tackling osteoarthritis may lead to treatment in five years

First Stem Cell Study of Bipolar Disorder Yields Promising Results

Posted: Published on March 26th, 2014

Contact Information Available for logged-in reporters only Newswise ANN ARBOR, Mich. What makes a person bipolar, prone to manic highs and deep, depressed lows? Why does bipolar disorder run so strongly in families, even though no single gene is to blame? And why is it so hard to find new treatments for a condition that affects 200 million people worldwide? New stem cell research published by scientists from the University of Michigan Medical School, and fueled by the Heinz C. Prechter Bipolar Research Fund, may help scientists find answers to these questions. The team used skin from people with bipolar disorder to derive the first-ever stem cell lines specific to the condition. In a new paper in Translational Psychiatry, they report how they transformed the stem cells into neurons, similar to those found in the brain and compared them to cells derived from people without bipolar disorder. The comparison revealed very specific differences in how these neurons behave and communicate with each other, and identified striking differences in how the neurons respond to lithium, the most common treatment for bipolar disorder. Its the first time scientists have directly measured differences in brain cell formation and function between people with bipolar … Continue reading →

Comments Off on First Stem Cell Study of Bipolar Disorder Yields Promising Results

Page 4,524«..1020..4,5234,5244,5254,526..4,5304,540..»